Dual-driven by regulatory science and policy reconstruction: Traditional Chinese medicine (TCM) new drugs accelerate development-A critical review of highlights in registration and regulation of TCM and natural medicine new drugs in China (2021-2025).

Zhao J et al.

NCBI PubMed Central · Papers · License: Open Access

computer science education

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 371678
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.